Welcome to our dedicated page for Lensar news (Ticker: LNSR), a resource for investors and traders seeking the latest updates and insights on Lensar stock.
LENSAR, Inc. (Nasdaq: LNSR) is a commercial-stage medical device and global medical technology company focused on advanced laser systems for the treatment of cataracts and the management of astigmatism. News about LENSAR often centers on its ALLY Robotic Cataract Laser System, financial performance, and the company’s pending acquisition by Alcon Research, LLC.
Regular earnings releases provide updates on quarterly revenue, procedure volumes performed on LENSAR’s installed base of laser systems, and the mix between system sales and recurring revenue from procedures, leases, and service. These reports also discuss non-GAAP metrics such as EBITDA and Adjusted EBITDA, along with commentary on operational initiatives and utilization of the ALLY system in the United States and abroad.
Another recurring news theme is corporate and capital markets activity. LENSAR has announced a definitive merger agreement under which Alcon intends to acquire the company, including the ALLY Robotic Cataract Laser Treatment System, Streamline software technology, and the LENSAR legacy laser system. Subsequent updates describe stockholder approval of the merger proposal and ongoing regulatory review, including interactions with the U.S. Federal Trade Commission.
LENSAR also issues announcements related to equity compensation, such as inducement grants of restricted stock units and stock options to newly hired non-executive employees under its Employment Inducement Incentive Award Plan. These items provide insight into hiring and compensation practices. Investors and observers who follow LNSR news can use this page to review earnings releases, merger-related developments, and governance and compensation updates in one place.
LENSAR, a global medical technology company specializing in advanced femtosecond laser solutions for cataracts, announced CEO Nick Curtis will present at two investor conferences. The BTIG Virtual MedTech Conference is scheduled for February 18, 2021, at 4:00 p.m. ET, followed by the SVB Leerink 10th Annual Global Healthcare Conference on February 25, 2021, at 3:40 p.m. ET. Investors can access live webcasts and replays on the Company’s website. LENSAR’s innovative laser system aims to enhance surgical outcomes through advanced imaging and precision.
LENSAR, Inc. (Nasdaq:LNSR) has expanded its Board of Directors to seven members with the appointments of Aimee S. Weisner and Elizabeth G. O’Farrell, effective February 1, 2021. Weisner will join the Compensation Committee, while O’Farrell will chair the Audit Committee. CEO Nick Curtis emphasized their expertise in global operations, finance, and regulatory environments, which will assist the company in achieving its strategic goals. The anticipated launch of the next-generation ALLY system is highlighted as a potential game-changer in cataract surgery.
LENSAR, Inc. (NASDAQ: LNSR), a leader in femtosecond laser surgical solutions for cataracts, announced CEO Nick Curtis will present at the 32nd Annual Piper Sandler Virtual Healthcare Conference. The presentation will be available on-demand starting November 23, 2020, at 10 a.m. Eastern Time via the Company’s website. Curtis will also hold one-on-one meetings with investors on December 1 and 2, 2020. Investors can request meetings through Piper Sandler or by contacting Lee Roth.
About LENSAR: LENSAR specializes in advanced laser systems aimed at enhancing surgical outcomes for cataract treatment.
LENSAR, Inc. (NASDAQ: LNSR) has announced the acceptance of three posters and one paper for virtual presentations at the Annual Meeting of the American Academy of Ophthalmology (AAO), scheduled for November 13-15, 2020. The paper, titled 'Refractive Outcomes of a Light-Adjustable IOL in Cataract Patients With a History of RK,' will be presented by Dr. James D. Lehmann. The accepted posters include studies on the management of astigmatism during cataract surgery, with presentations by Dr. Seong-Jun Lee and Dr. Vasilios F. Diakonis, available on the AAO meeting portal starting November 11, 2020.
LENSAR, Inc. (NASDAQ: LNSR) reported third-quarter 2020 revenue of $7.1 million, down from $8.1 million in Q3 2019 due to pandemic-related disruptions. The total number of procedures sold was 25,078, almost flat year-over-year. Gross margin improved to $3.9 million (55% of revenue), up from $3.3 million (41% of revenue) in Q3 2019. Operating loss decreased to $(4.7) million from $(5.3) million. LENSAR remains on track to launch its ALLY system in 2022, with sufficient capital to support operations through the filing of its FDA application. Cash and cash equivalents stood at $42.7 million as of September 30, 2020.
LENSAR, Inc. (NASDAQ: LNSR) has officially completed its spin-off from PDL BioPharma, Inc. (NASDAQ: PDLI), with shares beginning regular trading on NASDAQ. The distribution grants PDL stockholders 0.075879 shares of LENSAR for each share of PDL held as of September 22, 2020. LENSAR specializes in femtosecond laser surgical solutions for cataract treatment, utilizing advanced technologies to enhance surgical outcomes.